| dc.contributor.author | Gaikwad, Anil Bhanudas | |
| dc.date.accessioned | 2025-03-17T04:45:44Z | |
| dc.date.available | 2025-03-17T04:45:44Z | |
| dc.date.issued | 2024-11 | |
| dc.identifier.uri | https://www.tandfonline.com/doi/full/10.1080/14728222.2024.2421762 | |
| dc.identifier.uri | http://dspace.bits-pilani.ac.in:8080/jspui/handle/123456789/18384 | |
| dc.description.abstract | Globally, ~850 million people are affected by different kidney diseases. The pathogenesis of kidney diseases is intricate, where autophagy is crucial for maintaining kidney homeostasis. Iteliminates damaged organelles, thus reducing renal lesions and allowing tissue regeneration. Therefore, targeting various autophagy proteins, e.g. Unc–51–like autophagy-activating kinase 1 (ULK1), is emerging as potential therapeutic strategy against kidney disease. | en_US |
| dc.language.iso | en | en_US |
| dc.publisher | Taylor & Francis | en_US |
| dc.subject | Pharmacy | en_US |
| dc.subject | Autophagy | en_US |
| dc.subject | Kidney diseases | en_US |
| dc.subject | ULK1 | en_US |
| dc.subject | Therapeutic target | en_US |
| dc.subject | Kidney homeostasis | en_US |
| dc.title | ULK1 as a therapeutic target in kidney diseases: Current perspective | en_US |
| dc.type | Article | en_US |
| Files | Size | Format | View |
|---|---|---|---|
|
There are no files associated with this item. |
|||